00:32 · 12 āļ˜āļąāļ™āļ§āļēāļ„āļĄ 2023

Eli Lilly shares lose after negative obesity drug test results 🔎

Eli Lilly's (LLY.US) shares dip over 4.00% following a study published in The Journal of the American Medical Association revealed that patients who stopped using the company’s obesity drug, tirzepatide (marketed as Zepbound), regained weight. The drug initially led to a significant average weight reduction of 20.0% over 36 weeks of therapy. However, those who switched to a placebo after this period saw a 14% weight gain over the following 52 weeks. In contrast, patients who continued the treatment experienced an additional 5.5% weight loss. This peer-reviewed study, which enrolled 670 adults without diabetes but with obesity or overweight, was sponsored by Eli Lilly. The authors of the study acknowledged its limitations, including not adjusting doses post-randomization and not considering the impact of behavioral therapy on maintaining weight reduction.

In a similar vein, a study funded by Novo Nordisk, Eli Lilly's competitor in the weight loss sector, showed that patients using their weight loss drug, semaglutide, regained two-thirds of their lost weight a year after stopping the treatment.

Following an unfavorable report, Eli Lilly's shares are losing over 4.00% today. The stock prices are falling below the lower boundary of the upward channel in which the shares have remained since the beginning of this year. Source: xStation 5

āļĢāļąāļš Welcome Bonus 10% āđ€āļĄāļ·āđˆāļ­āđ€āļĢāļīāđˆāļĄāđ€āļ—āļĢāļ”āļāļąāļš XTB

āļĢāļąāļš Welcome Bonus 10% āđ€āļĄāļ·āđˆāļ­āđ€āļĢāļīāđˆāļĄāđ€āļ—āļĢāļ”āļāļąāļš XTB

āđ€āļĢāļīāđˆāļĄāļ•āđ‰āļ™āļ‡āđˆāļēāļĒ āđ† āđ€āļžāļĩāļĒāļ‡āđ€āļ›āļīāļ”āļšāļąāļāļŠāļĩāđāļĨāļ°āļāļēāļāđ€āļ‡āļīāļ™āļ„āļĢāļąāđ‰āļ‡āđāļĢāļ āļāđ‡āļĢāļąāļšāđ‚āļšāļ™āļąāļŠāļŠāļđāļ‡āļŠāļļāļ” 10 USD āđ€āļ‚āđ‰āļēāļšāļąāļāļŠāļĩāđ€āļ—āļĢāļ”āļ‚āļ­āļ‡āļ„āļļāļ“āđ‚āļ”āļĒāļ•āļĢāļ‡ āļžāļĢāđ‰āļ­āļĄāđ€āļ—āļĢāļ” āļŸāļ­āđ€āļĢāđ‡āļāļ‹āđŒ āļ—āļ­āļ‡āļ„āļģ āļ”āļąāļŠāļ™āļĩāđāļĨāļ°āļŠāļīāļ™āļ—āļĢāļąāļžāļĒāđŒāļ­āļ·āđˆāļ™ āđ†Â āļ­āļĩāļāļĄāļēāļāļĄāļēāļĒ 

āļĢāļąāļšāđ‚āļšāļ™āļąāļŠ 10% āļĢāļąāļšāđ‚āļšāļ™āļąāļŠ 10% āļĢāļąāļšāđ‚āļšāļ™āļąāļŠ 10% āļĢāļąāļšāđ‚āļšāļ™āļąāļŠ 10%
19 āļžāļĪāļĻāļˆāļīāļāļēāļĒāļ™ 2026, 16:30

Nvidia - āļĢāđˆāļ§āļ‡āļĨāļ‡ 40% āļˆāļēāļāļˆāļļāļ”āļŠāļđāļ‡āļŠāļļāļ” āļĒāļąāļ‡āļĄāļĩāđ‚āļ­āļāļēāļŠāļŸāļ·āđ‰āļ™āļ•āļąāļ§āļŦāļĢāļ·āļ­āđ„āļĄāđˆ?

19 āļžāļĪāļĻāļˆāļīāļāļēāļĒāļ™ 2026, 14:23

Morning Wrap: āļˆāļąāļšāļ•āļē IPO āļ„āļĢāļąāđ‰āļ‡āļ›āļĢāļ°āļ§āļąāļ•āļīāļĻāļēāļŠāļ•āļĢāđŒ āļ•āļĨāļēāļ”āļŦāļļāđ‰āļ™āļ„āļĢāļąāđ‰āļ‡āđƒāļŦāļāđˆāļ—āļĩāđˆāļŠāļļāļ”!

19 āļžāļĪāļĻāļˆāļīāļāļēāļĒāļ™ 2026, 08:45

āđ€āļ‡āļīāļ™āļĨāļ‡āļ—āļļāļ™āđāļŦāđˆāđ€āļ‚āđ‰āļē IPO āļ‚āļ­āļ‡ Anthropic āđƒāļ™āļŠāļąāļ›āļ”āļēāļŦāđŒāđ€āļ”āļĩāļĒāļ§āļāļąāļšāļ—āļĩāđˆāļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒāļ‚āļ­āļ‡āļšāļĢāļīāļĐāļąāļ—āļ–āļđāļāļ•āļąāđ‰āļ‡āļ„āļģāļ–āļēāļĄ

19 āļžāļĪāļĻāļˆāļīāļāļēāļĒāļ™ 2026, 08:18

📉 Fed āļŠāđˆāļ‡āļŠāļąāļāļāļēāļ“āđ€āļ‚āđ‰āļĄāļ‡āļ§āļ” Nvidia āđāļœāđˆāļ§ āļāļ”āļ”āļąāļ™āļ•āļĨāļēāļ” āļ—āļ­āļ‡āļ„āļģāđƒāļāļĨāđ‰ 3,700 āļ”āļ­āļĨāļĨāļēāļĢāđŒ

āļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļ—āļēāļ‡āļāļēāļĢāđ€āļ‡āļīāļ™āļ—āļĩāđˆāđ€āļĢāļēāđƒāļŦāđ‰āļšāļĢāļīāļāļēāļĢāļĄāļĩāļ„āļ§āļēāļĄāđ€āļŠāļĩāđˆāļĒāļ‡ āđ€āļĻāļĐāļŦāļļāđ‰āļ™ (Fractional Shares) āđ€āļ›āđ‡āļ™āļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļ—āļĩāđˆāđƒāļŦāđ‰āļšāļĢāļīāļāļēāļĢāļˆāļēāļ XTB āđāļŠāļ”āļ‡āļ–āļķāļ‡āļāļēāļĢāđ€āļ›āđ‡āļ™āđ€āļˆāđ‰āļēāļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļšāļēāļ‡āļŠāđˆāļ§āļ™āļŦāļĢāļ·āļ­ ETF āđ€āļĻāļĐāļŦāļļāđ‰āļ™āđ„āļĄāđˆāđƒāļŠāđˆāļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļ—āļēāļ‡āļāļēāļĢāđ€āļ‡āļīāļ™āļ­āļīāļŠāļĢāļ° āļŠāļīāļ—āļ˜āļīāļ‚āļ­āļ‡āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ­āļēāļˆāļ–āļđāļāļˆāļģāļāļąāļ”
āļ„āļ§āļēāļĄāļŠāļđāļāđ€āļŠāļĩāļĒāļŠāļēāļĄāļēāļĢāļ–āđ€āļāļīāļ™āļāļ§āđˆāļēāđ€āļ‡āļīāļ™āļ—āļĩāđˆāļāļēāļ